Bouquet J, Sinaasappel M, Neijens H J
Department of Pediatrics, Erasmus University, Rotterdam, The Netherlands.
J Pediatr Gastroenterol Nutr. 1988;7 Suppl 1:S30-5. doi: 10.1097/00005176-198811001-00007.
Malabsorption of nutrients in cystic fibrosis (CF) has a multifactorial origin. The factors involved in malabsorption include malfunction of the exocrine pancreas and liver, bile acid metabolism, and disordered intestinal resorptive processes. Therapeutic measures presently employed are only partially effective. Improvement of fat malabsorption is attained by using a pancreatic enzyme supplement consisting of pH-sensitive, enteric-coated microspheres (microsphere preparations) that prevent enzyme degradation in the stomach and travel with the chyme to the small intestine. Microsphere preparations, however, do not improve bile salt deficiency. The detergent Tween-80, given orally to simulate bile salt activity, does not improve fat absorption. The mucus viscosity is probably enhanced in the intestinal epithelium of CF patients and can be decreased by N-acetylcysteine, which breaks down sulfide bonds. However, the addition of a high oral dose of this mucus solvent to pancreatin preparations does not improve fat absorption. Further studies on the disturbed intestinal resorptive mechanism seem warranted since recent investigations point to an abnormal chloride secretion as the primary defect in the intestinal epithelia of CF patients.
囊性纤维化(CF)患者的营养物质吸收不良有多种因素。参与吸收不良的因素包括外分泌胰腺和肝脏功能障碍、胆汁酸代谢以及肠道吸收过程紊乱。目前采用的治疗措施仅部分有效。通过使用由对pH敏感的肠溶微球组成的胰酶补充剂(微球制剂)来改善脂肪吸收不良,这种微球制剂可防止酶在胃中降解,并随食糜进入小肠。然而,微球制剂并不能改善胆盐缺乏。口服去污剂吐温80以模拟胆盐活性,并不能改善脂肪吸收。CF患者肠上皮细胞中的黏液黏度可能会增加,而N - 乙酰半胱氨酸可降低这种黏度,它能分解硫化物键。然而,在胰酶制剂中添加高剂量的这种黏液溶剂并不能改善脂肪吸收。鉴于最近的研究指出异常的氯离子分泌是CF患者肠上皮细胞的主要缺陷,对肠道吸收机制紊乱进行进一步研究似乎是必要的。